Norovirus Immunity and the Great Escape

1. DonaldsonEF, LindesmithLC, LobueAD, BaricRS (2010) Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 8: 231–241.

2. PatelMM, WiddowsonMA, GlassRI, AkazawaK, VinjeJ, et al. (2008) Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 14: 1224–1231.

3. ZhengDP, AndoT, FankhauserRL, BeardRS, GlassRI, et al. (2006) Norovirus classification and proposed strain nomenclature. Virology 346: 312–323.

4. FankhauserRL, MonroeSS, NoelJS, HumphreyCD, BreseeJS, et al. (2002) Epidemiologic and molecular trends of “Norwalk-like viruses” associated with outbreaks of gastroenteritis in the United States. J Infect Dis 186: 1–7.

5. LindesmithLC, BeltramelloM, DonaldsonEF, CortiD, SwanstromJ, et al. (2012) Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 8: e1002705 doi:10.1371/journal.ppat.1002705.

6. LindesmithLC, DonaldsonEF, LobueAD, CannonJL, ZhengD-P, et al. (2008) Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 5: e31 doi:10.1371/journal.pmed.0050031.

7. LindesmithLC, DebbinkK, SwanstromJ, VinjeJ, CostantiniV, et al. (2012) Monoclonal antibody-based antigenic mapping of norovirus GII.4–2002. J Virol 86: 873–883.

8. DebbinkK, DonaldsonEF, LindesmithLC, BaricRS (2012) Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 86: 1214–1226.

9. ParraGI, AbenteEJ, Sandoval-JaimeC, SosnovtsevSV, BokK, et al. (2012) Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-Blood group antigens. J Virol 86: 7414–26.

10. LindesmithL, MoeC, MarionneauS, RuvoenN, JiangX, et al. (2003) Human susceptibility and resistance to Norwalk virus infection. Nat Med 9: 548–553.

11. HuangP, FarkasT, MarionneauS, ZhongW, Ruvoen-ClouetN, et al. (2003) Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 188: 19–31.

12. HuangP, FarkasT, ZhongW, TanM, ThorntonS, et al. (2005) Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 79: 6714–6722.

13. LindesmithL, MoeC, LependuJ, FrelingerJA, TreanorJ, et al. (2005) Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 79: 2900–2909.

14. de RougemontA, Ruvoen-ClouetN, SimonB, EstienneyM, Elie-CailleC, et al. (2011) Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol 85: 4057–4070.

15. ReeckA, KavanaghO, EstesMK, OpekunAR, GilgerMA, et al. (2010) Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 202: 1212–1218.

16. ParrinoTA, SchreiberDS, TrierJS, KapikianAZ, BlacklowNR (1977) Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 297: 86–89.

17. AtmarRL, BernsteinDI, HarroCD, Al-IbrahimMS, ChenWH, et al. (2011) Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 365: 2178–2187.

18. JohnsonPC, MathewsonJJ, DuPontHL, GreenbergHB (1990) Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 161: 18–21.

19. SiebengaJJ, LemeyP, Kosakovsky PondSL, RambautA, VennemaH, et al. (2010) Phylodynamic reconstruction reveals norovirus GII.4 epidemic expansions and their molecular determinants. PLoS Pathog 6: e1000884 doi:10.1371/journal.ppat.1000884.

20. LindesmithLC, DonaldsonE, LeonJ, MoeCL, FrelingerJA, et al. (2010) Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 84: 1800–1815.

21. CannonJL, LindesmithLC, DonaldsonEF, SaxeL, BaricRS, et al. (2009) Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol 83: 5363–5374.

22. RockxB, BaricRS, de GrijsI, DuizerE, KoopmansMP (2005) Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol 77: 439–446.

23. LindesmithLC, DonaldsonEF, BaricRS (2011) Norovirus GII.4 strain antigenic variation. J Virol 85: 231–242.

24. LoBueAD, LindesmithL, YountB, HarringtonPR, ThompsonJM, et al. (2006) Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 24: 5220–5234.

25. ParraGI, BokK, TaylorR, HaynesJR, SosnovtsevSV, et al. (2012) Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 30: 3580–6.

26. HaleAD, TanakaTN, KitamotoN, CiarletM, JiangX, et al. (2000) Identification of an epitope common to genogroup 1 “norwalk-like viruses”. J Clin Microbiol 38: 1656–1660.

27. ParkerTD, KitamotoN, TanakaT, HutsonAM, EstesMK (2005) Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol 79: 7402–7409.

28. AllenDJ, NoadR, SamuelD, GrayJJ, RoyP, et al. (2009) Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding. Virol J 6: 150.

29. HansmanGS, BiertumpfelC, GeorgievI, McLellanJS, ChenL, et al. (2011) Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. J Virol 85: 6687–6701.

30. JohnstonCP, QiuH, TicehurstJR, DicksonC, RosenbaumP, et al. (2007) Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis 45: 534–540.